The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

Cineplex Inc . (TSX:CGX) stock rose 5% Friday after the company announced that longtime President and CEO Ellis Jacob will retire on December 31, 2026.

Microsoft (NASDAQ:MSFT) stock fell 0.5% in pre-market trading on Friday following a report from The Information that the company’s next-generation AI chip is facing a delay of at least six months.

Boeing is entering a new phase of recovery that could support a market reassessment of its stock, according to analysts at Redburn.

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...

Guggenheim raised its price target on Walt Disney (NYSE:DIS) Co to $140 from $120 on stronger-than-expected trends across sports advertising, theme parks, and progress on cost-cutting as the company ...

Recombinant therapeutics market surges to $960.4B by 2035, fueled by biotech advances, targeted therapies, and rising global ...